8-K: Allakos Inc. Completes Merger with Concentra Biosciences, Delisting from Nasdaq

Allakos Inc. finalizes its merger with Concentra Biosciences, resulting in the company becoming a wholly-owned subsidiary and delisting from the Nasdaq Global Select Market.

Summary

• Allakos Inc. has completed its merger with Concentra Biosciences, LLC, effective May 15, 2025.
• Concentra Merger Sub III, Inc., a subsidiary of Concentra, completed a tender offer to purchase all outstanding shares of Allakos common stock for $0.33 per share.
• Approximately 81.21% of the outstanding shares, totaling 73,398,243 shares, were validly tendered and not withdrawn.
• The tender offer expired on May 14, 2025, and all conditions were satisfied.
• Following the tender offer, Merger Sub merged with Allakos, with Allakos continuing as the surviving corporation and a wholly-owned subsidiary of Concentra.
• Each outstanding share was converted into the right to receive $0.33 in cash, excluding treasury shares, shares owned by Parent or Merger Sub, and shares held by stockholders demanding appraisal.
• In-the-Money Options were cancelled and converted into the right to receive cash equal to the excess of the Offer Price over the exercise price.
• Out-of-the-Money Options were cancelled for no consideration.
• Allakos Restricted Stock Units (RSUs) vested in full and were converted into the right to receive cash equal to the Offer Price.
• Allakos has requested Nasdaq to suspend trading of its shares and file a Form 25 to delist the shares from Nasdaq and deregister them under the Securities Exchange Act of 1934.
• The Surviving Corporation intends to file a Form 15 to terminate the registration of the shares and suspend reporting obligations.
• Robert Alexander, Robert E. Andreatta, Neil Graham, Steven P. James, Amy L. Ladd, Dolca Thomas, and Paul Walker resigned from the board of directors, and Dr. Alexander, Baird Radford, and Adam Tomasi resigned as officers.
• The directors and officers of Merger Sub immediately prior to the merger became the directors and officers of the Surviving Corporation.
• The Companys certificate of incorporation and bylaws were amended and restated.

Sentiment

Score: 3

Explanation: The sentiment is low due to the low acquisition price and delisting, indicating a poor outcome for previous investors. The company is now private and will be controlled by Concentra.

Positives

• The merger provides Allakos stockholders with immediate cash at $0.33 per share.
• The completion of the merger provides certainty for the future of the company under new ownership.

Negatives

• Allakos shareholders who did not tender their shares will receive $0.33 per share, which may be viewed negatively if they believed the company was worth more.
• The delisting from Nasdaq means the shares will no longer be publicly traded.

Risks

• The integration of Allakos into Concentra Biosciences may present operational challenges.
• There is a risk that the expected benefits of the merger may not be fully realized.

Future Outlook

The company will operate as a wholly-owned subsidiary of Concentra Biosciences, LLC. The future direction and strategy will be determined by Concentra.

Industry Context

This merger reflects a trend of consolidation in the biotechnology industry, where smaller companies are often acquired by larger entities to leverage resources and expertise.

Comparison to Industry Standards

• It is difficult to compare this merger to industry standards without knowing the specific financial details and strategic rationale behind Concentra's acquisition of Allakos.
• However, similar acquisitions in the biotech space often involve larger premiums paid to shareholders, depending on the target company's pipeline and market potential.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders receive $0.33 per share.
• Employees face uncertainty regarding their future roles within the combined company.
• Customers and partners may experience changes as the company integrates with Concentra Biosciences.

Next Steps

• Filing of Form 25 with the SEC to delist shares from Nasdaq.
• Filing of Form 15 with the SEC to terminate registration of shares and suspend reporting obligations.
• Integration of Allakos into Concentra Biosciences.

Key Dates

Keywords

Merger, Acquisition, Allakos, Concentra Biosciences, Delisting, Tender Offer, Nasdaq, Shares, Stock, Directors, Officers